International Journal of Molecular Sciences Review Hypoxia Pathway Proteins are Master Regulators of Erythropoiesis Deepika Watts 1, Diana Gaete 1 , Diego Rodriguez 1, David Hoogewijs 2, Martina Rauner 3, Sundary Sormendi 1 and Ben Wielockx 1,* 1 Institute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, 01307 Dresden, Germany;
[email protected] (D.W.);
[email protected] (D.G.);
[email protected] (D.R.);
[email protected] (S.S.) 2 Section of Medicine, Department of Endocrinology, Metabolism and Cardiovascular System, University of Fribourg, 1700 Fribourg, Switzerland;
[email protected] 3 Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, 01307 Dresden, Germany;
[email protected] * Correspondence:
[email protected]; Tel.: +49-351-458-16260 Received: 3 October 2020; Accepted: 28 October 2020; Published: 30 October 2020 Abstract: Erythropoiesis is a complex process driving the production of red blood cells. During homeostasis, adult erythropoiesis takes place in the bone marrow and is tightly controlled by erythropoietin (EPO), a central hormone mainly produced in renal EPO-producing cells. The expression of EPO is strictly regulated by local changes in oxygen partial pressure (pO2) as under-deprived oxygen (hypoxia); the transcription factor hypoxia-inducible factor-2 induces EPO. However, erythropoiesis regulation extends beyond the well-established hypoxia-inducible factor (HIF)–EPO axis and involves processes modulated by other hypoxia pathway proteins (HPPs), including proteins involved in iron metabolism. The importance of a number of these factors is evident as their altered expression has been associated with various anemia-related disorders, including chronic kidney disease.